During April 2024, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the completion of the rights issue of units which was resolved by the Board of Directors on 8 February 2024 and approved by the Extraordinary General Meeting held on 14 March 2024. As of 30 April 2024, the total number of outstanding shares in Alligator amounts to 758,989,086, whereof 758,039,236 are ordinary shares with one vote each and 949,850 are series C shares with 1/10 vote each. The total number of votes as of 30 April 2024 amounts to 758,134,221.

For further information, please contact:

Søren Bregenholt, CEO
E-mail: soren.bregenholt@alligatorbioscience.com
Phone: +46 (0) 46 540 82 00

This information is information that Alligator Bioscience is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-04-30 08:30 CEST.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime®, and novel drug candidates based on the RUBY® bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Attachments

Change in number of shares and votes in Alligator Bioscience AB

© Modular Finance, source Nordic Press Releases